NEVVI Medicare utilization intelligence

← back

STEWART, JEFFREYMD NPI 1982715892 Clinician

Hematology-Oncology · MIDDLETOWN, NY

Specialty Hematology-Oncology — from billed Medicare claims
Trained UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE — medical school, self-reported to CMS
In practice about 38 years since medical school (class of 1988, self-reported to CMS)
Location MIDDLETOWN, NY · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 51 codes billed · 35,013 disclosed volume (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
CRYSTAL RUN HEALTHCARE PHYSICIANS LLP
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2020-10

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed submitted charges across all codes were in CY2024. Included with Platform.

  • Charge, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Volume Beneficiary-episodes Avg charge Avg Medicare payment
J1453 Injection, fosaprepitant, 1 mg
J9271 Injection, pembrolizumab, 1 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J1626 Injection, granisetron hydrochloride, 100 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J1100 Injection, dexamethasone sodium phosphate, 1 mg
80053 Blood test, comprehensive group of blood chemicals
J1750 Injection, iron dextran, 50 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96375 Injection of additional new drug or substance into vein
J9045 Injection, carboplatin, 50 mg
96413 Administration of chemotherapy into vein, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
82728 Ferritin (blood protein) level
83615 Lactate dehydrogenase (enzyme) level
J3490 Unclassified drugs
85610 Blood test, clotting time
93793 Anticoagulant management of patient taking warfarin
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
82378 Carcinoembryonic antigen (cea) protein level
85045 Red blood count, automated test
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
84153 Psa (prostate specific antigen) measurement, total
96361 Infusion into a vein for hydration, each additional hour
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
82607 Cyanocobalamin (vitamin b-12) level
96417 Administration of additional new drug or substance into vein, 1 hour or less
80048 Blood test, basic group of blood chemicals (calcium, total)
J1200 Injection, diphenhydramine hcl, up to 50 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
82746 Folic acid level, serum
96415 Administration of chemotherapy into vein, each additional hour
84154 Psa (prostate specific antigen) measurement, free
84466 Transferrin (iron binding protein) level
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96411 Administration of additional new drug or substance into vein using push technique
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
84443 Blood test, thyroid stimulating hormone (tsh)
83735 Magnesium level
85730 Coagulation assessment blood test, plasma or whole blood
86140 Measurement c-reactive protein for detection of infection or inflammation
85651 Red blood cell sedimentation rate, to detect inflammation, non-automated
38222 Biopsy and aspiration of bone marrow sample for diagnosis
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous
82565 Blood creatinine level
84520 Urea nitrogen level to assess kidney function, quantitative

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.